Application of pomegranate in preparing medicament for treating or preventing hepatitis B virus infection

A technology of hepatitis B virus and pomegranate extract, applied in the field of medicine, can solve the problems of no application of ellagic acid, etc., and achieve the effects of improving treatment quality, medication compliance, high bioavailability, and clear metabolic pathway

Inactive Publication Date: 2012-08-15
陈绪林
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although it has been reported that ellagic acid isolated from Phyllanthus phylloxera can inhibit the secretion of HBeAg, there is no report on the effect of gallic acid and pomegranate tannin on the anti-hepatitis B virus, and there is no report on the effect of ellagic acid, gallic acid and Application of pomegranate skin tannin in anti-hepatitis B virus

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of pomegranate in preparing medicament for treating or preventing hepatitis B virus infection
  • Application of pomegranate in preparing medicament for treating or preventing hepatitis B virus infection
  • Application of pomegranate in preparing medicament for treating or preventing hepatitis B virus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Example 1: Evaluation of anti-HBV activity of punicalagin, ellagic acid, gallic acid and pomegranate tannin

[0045] 1. Experimental materials

[0046] 1.1 Cells and Drugs

[0047] HepG2.117 cell: Human liver cancer cell line, the HBV genome is integrated in the chromosome, which can support HBV DNA synthesis, protein expression, and produce infectious virus particles. This cell line was donated by Professor Michael Nassal of the University of Freiburg in Germany and researcher Hu Kanghong of the Wuhan Institute of Virology. Picalagin, ellagic acid, and gallic acid were purchased from Sichuan Weikeqi Biotechnology Co., Ltd., and pomegranate tannin was purchased from Shanghai Branch of Wuhan Yitai Technology Co., Ltd.

[0048] 1.2 Reagents

[0049] DMEM medium and fetal bovine serum (FBS) were purchased from GIBCO; HBV surface antigen (S antigen) and e antigen detection kits were purchased from Shanghai Kehua Biotechnology Co., Ltd.; Alamarblue reagent was purchased f...

Embodiment 2

[0058] Example 2: Punicalagin acts directly on cccDNA in the nucleus of liver cells to exert antiviral effect

[0059] 1. Experimental materials

[0060] 1.1 Cells, plasmids and drugs

[0061] HepG2.117 cell: Human liver cancer cell line, the HBV genome is integrated in the chromosome, which can support HBV DNA synthesis, protein expression, and produce infectious virus particles. This cell line was donated by Professor Michael Nassal of the University of Freiburg, Germany, and researcher Hu Kanghong of the Wuhan Institute of Virology. HepG2.2.15 is a human liver cancer cell, donated by Chen Xinwen, a researcher at Wuhan Institute of Virology; punicalagin was purchased from Sichuan Weikeqi Biotechnology Co., Ltd.; Lamivudine was a gift from NIH.

[0062] 1.2 Reagents

[0063] DMEM medium was purchased from GIBCO, Real-time PCR kit was purchased from TOYOBO, and Trizol reagent was purchased from Roche.

[0064] 2. Experimental methods and results

[0065] 2.1 Detection of ...

Embodiment 3

[0074] Example 3: Combination of punicalagin and lamivudine

[0075] 1. Experimental materials

[0076] 1.1 Cells, plasmids and drugs

[0077] HepG2.117 cell: Human liver cancer cell line, the HBV genome is integrated in the chromosome, which can support HBV DNA synthesis, protein expression, and produce infectious virus particles. This cell line was donated by Professor Michael Nassal of the University of Freiburg, Germany, and researcher Hu Kanghong of the Wuhan Institute of Virology. HepG2.2.15 is a human liver cancer cell, donated by Chen Xinwen, a researcher at Wuhan Institute of Virology; punicalagin was purchased from Sichuan Weikeqi Biotechnology Co., Ltd.; Lamivudine was a gift from NIH.

[0078] 1.2 Reagents

[0079] DMEM medium was purchased from GIBCO, and Real-time PCR kit was purchased from TOYOBO. 2. Experimental methods and results

[0080] HepG2.117 and HepG2.2.15 cells were divided into 4×10 4 Cells / well were seeded in 24-well cell culture plates, cultur...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of pomegranate in preparing a medicament for treating or preventing hepatitis B virus (HBV) infection. The application is implemented through the following steps: detecting the cytotoxicity of each pomegranate sourced medicament to HepG2.117, wherein the CC50 of punicalagin, gallic acid and punicalin is sequentially more than 500mu M, 334mu M and 218.86mu M; and then detecting the effects of the punicalagin, ellagic acid, gallic acid and punicalin to HBeAg and HBsAg, and the effect of punicalagin to DNA (deoxyribonucleic acid) and RNA (ribonucleic acid) of virus. Results indicate that the four compounds can be used for inhibiting HBeAg and HBsAg, wherein the punicalagin can be used for remarkably reducing the cccDNA (covalently closed circular DNA). The punicalagin can be used for remarkably reducing the contents of HBeAg and cccDNA in an HepG2.2.15 cell, and does not have effect to the total HBV DNA in the cell, which indicates that the punicalagin takes the cccDNA as a target to directly clear the cccDNA in a liver cell. Currently, the anti-HBV infection medicament in clinical treatment cannot directly act on the cccDNA, and cannot completely remove the virus. Experiment results disclose that the medicament has the prospect of being developed into anti-HBV infection medicaments.

Description

technical field [0001] The invention belongs to the technical field of medicines, and more specifically relates to the application of a pomegranate in the preparation of medicines for treating or preventing hepatitis B virus infection. Background technique [0002] Hepatitis B virus (HBV), discovered in the 1960s, is the pathogen of hepatitis B. Hepatitis B virus infection is one of the main causes of chronic hepatitis, liver cirrhosis, and liver cancer worldwide. HBV is mainly transmitted through blood, sex, mother to child and other ways. 1 / 4 of the world's people live in HBV-endemic areas, 2 billion people are HBV carriers, of which 350 to 400 million people are chronically infected, and nearly 1 million people die of liver cirrhosis and liver function caused by HBV every year failure and liver cancer. [0003] HBV is a member of the genus Mammalian virus of the family Hepadnaviridae. The complete HBV particle is only 42nm in diameter, also known as Dane particle, whi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/185A61K31/7048A61K31/366A61K31/192A61K31/513A61P31/20A61P1/16
Inventor 陈绪林刘春兰
Owner 陈绪林
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap